Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 769 results for "erbitux"

Merck KGaA Names Pharmaceutical Head Oschmann Deputy CEO

Merck KGaA, the German maker of Erbitux cancer medicine, promoted Stefan Oschmann to deputy chief executive officer and appointed Belen Garijo as its first female board member. Oschmann, currently head of the pharmaceutical unit, and Garijo, now ... BusinessWeek, 2 months ago

Putting the Patient First: Merck Serono to Present Data That Embodies the ESMO 2014 Theme of

ESMO 2014 Abstract #: Physician biomarker survey: 1080O_PR; Erbitux: CRYSTAL: 541P; LASCCHN: 993PD; DIRECT: 996P; Pipeline: pimasertib: 443O; c-Met: 1333TiP, 450PD, 744TiP, 745TiP; further pipeline: 772P, 507PD, 1235P ...
 Newswit.com1 month ago Merck KGaA : Putting the Patient First: Merck Serono to Present Data That Embodies the ESMO 2014 Theme of Precision Medicine in Cancer Care  4 Traders2 months ago Merck on Track with Pharma Strategy  Bionity.com2 months ago Merck KGaA : on Track with Pharma Strategy; Pipeline Progress Announced  4 Traders2 months ago
[x]  

Eli Lilly : Trademark Application for "ERBITUX CETUXIMAB" Filed

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a trademark application has been made for "ERBITUX CETUXIMAB" by Robert E. Lee , Jr., representing ...
 4 Traders1 month ago Researchers Submit Patent Application, "Predicting Response to Egfr Inhibitors", for Approval  4 Traders3 weeks ago Genovis : Researchers Submit Patent Application, "Endoglycosidase from Streptococcus Pyogenes and Methods Using It", for Approval  4 Traders1 month ago

Antibodies in Oncology Drug Pipeline Update 2014

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of ...
 Global Information Inc3 weeks ago
Securities Technology Monitor

Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer

Former Executive Director, Section Head Oncology Clinical Development at Merck & Co., Inc. and Director of Erbitux Medical Strategy at Bristol-Myers Squibb to Oversee Advaxis's Clinical Programs PRINCETON, N.J., Oct. 20, 2014 (GLOBE NEWSWIRE) -- ...
 Securities Technology Monitor1 month ago Advaxis, Inc. Appoints David J. Mauro, M.D., Ph.D., As Chief Medical Officer  FierceBiotech1 month ago Advaxis, Inc. Appoints As Chief Medical Officer  BioSpace1 month ago Advaxis : Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer  4 Traders1 month ago
[x]  

The Oncology Institute of Hope and Innovation Offers New Clinical Trials this Holiday Season

Below are currently opened clinical trials. If you would like more information or are interested in referring a patient to one of these trials, please contact Hilda Agajanian at (562) 869-1201. AML Celgene CC-486-AML-001: A Phase 3, Randomized, ...
 Stock Nod20 hours ago
[x]  
MedIndia

AAAS Names Eight Faculty Members from MD Anderson Cancer ...

The University of Texas MD Anderson Cancer Center has confirmed that eight of its faculty members have been named as Fellows by the American Association for the Advancement of Science. The Fellows selected to receive this highly recognized honor ...
 MedIndia1 day ago

Eight MD Anderson faculty named as AAAS fellows

PUBLIC RELEASE DATE: 24-Nov-2014 Their responsibilities may range from exploring the intricacies of biostatistics to bringing new drugs more rapidly to the patient, but eight faculty members from The University of Texas MD Anderson Cancer Center ...
 EurekAlert!2 days ago
Jutia Group

Market Update: Bristol-Myers Squibb Company (NYSE:BMY) Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor T

[GlobeNewswire] NEW YORK and SOUTH SAN FRANCISCO, Calif. — Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. today announced that they have entered into an exclusive clinical collaboration agreement to evaluate … Read more on ...
 Jutia Group2 days ago Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting  Jutia Group2 weeks ago Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment  Jutia Group1 month ago Stock Update (NYSE:BMY): Bristol immunotherapy gets 6-month U.S. FDA review for melanoma  Jutia Group2 months ago

Big Data in Oncology: Costly Fad or Invaluable Tool?

"Big data" is a buzz phrase that oncologists have been hearing for a while now. Some of the biggest names in cancer — Memorial Sloan Kettering in New York City, M.D. Anderson in Houston, Johns Hopkins in Baltimore, and the American Society of ...
 Medscape2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less